Concepedia

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors

Malcolm J. Moore, Holger W. Hirte, Lillian L. Siu, Amit M. Oza, Sébastien J. Hotte, Oana Petrenciuc, Frank Cihon, Chetan Lathia, Brian Schwartz

Annals of Oncology · 2005 · 301 citations · 16 references

Concepts

PharmacyPharmacokineticsPharmacologyCancer PharmacologyOncology PharmacotherapySolid Tumor PharmacotherapyOncology PharmacologyPharmacokinetics Of Anticancer DrugsToxicity ManagementTyrosine Kinase InhibitorsRaf SignalingRaf-mek-erk SignalingRefractory Solid TumorsTargeted Kinase InhibitionTherapeutic Tyrosine Kinase InhibitorsTyrosine Kinase Inhibitor PharmacokineticsTyrosine Kinase Inhibitor TherapyVegfr Inhibitors

References

16

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

Medicine, Oncology, Cancer Pharmacology +12

Mutations of the BRAF gene in human cancer

Helen Davies, Graham R. Bignell, Charles Cox et al. · Nature · 2002 · 10.7K citations

Medicine, Genetics, Molecular Genetics +12

ras oncogenes in human cancer: a review.

Joyce Bos · PubMed · 1989 · 5.1K citations

Medicine, Genetics, Oncology +17

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

Medicine, Oncology, Pharmacology +17

The role of angiogenesis in tumor growth.

J Folkman · PubMed · 1992 · 1.3K citations

Medicine, Cancer Biology, Oncology +12